ArticleEmerging infectious diseases2005
Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance.
Article in Emerging infectious diseases, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 116 citations in OpenAlex.
- Trial
- Genomic and phenotypic characterization of a multidrug-resistant Streptococcus pneumoniae 19 F ST320 isolate from a pediatric SARS-CoV-2 case in Yogyakarta, Indonesia.Scientific reports · 2026Article
- Large-scale global molecular epidemiology of antibiotic resistance determinants inMicrobial genomics · 2025Article
- Screening of in vitro antimicrobial activity of plants used in traditional Indonesian medicine.Pharmaceutical biology · 2018Article
- Synthesis and antibacterial activity of novel 11-[3-[(arylcarbamoyl)oxy]propylamino]-11-deoxy-6-O-methyl-3-oxoerythromycin A 11-N,12-O-cyclic carbamate derivatives.The Journal of antibiotics · 2016Article
- Determination of Characteristics of Erythromycin Resistant Streptococcus pneumoniae with Preferred PCV Usage in Iran.PloS one · 2016Article
- Emerging non-PCV13 serotypes of noninvasive Streptococcus pneumoniae with macrolide resistance genes in northern Japan.New microbes and new infections · 2016Article
- The Value of Macrolide-Based Regimens for Community-Acquired Pneumonia.Current infectious disease reports · 2015Article
- Mobile elements and chromosomal changes associated with MLS resistance phenotypes of invasive pneumococci recovered in the United States.Microbial drug resistance (Larchmont, N.Y.) · 2015Article
- Resistance determinants and their association with different transposons in the antibiotic-resistant Streptococcus pneumoniae.BioMed research international · 2015Article
- Phenotypes and genotypes of macrolide-resistant streptococcus pneumoniae.Balkan medical journal · 2015Article
- Increase in the rate of azithromycin-resistant Streptococcus pneumoniae isolates carrying the erm(B) and mef(A) genes in Taiwan, 2006-2010.BMC infectious diseases · 2014Article
- Molecular resistance mechanisms of macrolide-resistant invasive Streptococcus pneumoniae isolates from Alaska, 1986 to 2010.Antimicrobial agents and chemotherapy · 2013Article
- Serotype distribution and antibiotics susceptibility pattern of Streptococcus pneumonia in Iran.Iranian Red Crescent medical journal · 2013Article
- Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance.Journal of Korean medical science · 2013Review
- Macrolide resistance determinants among Streptococcus pneumoniae isolates from carriers in Central Greece.BMC infectious diseases · 2012Article
- Pneumonia Due to Drug-Resistant Streptococcus pneumoniae.Current infectious disease reports · 2012Article
- Dominance of multidrug resistant CC271 clones in macrolide-resistant streptococcus pneumoniae in Arizona.BMC microbiology · 2012Article
- Molecular typing methods for outbreak detection and surveillance of invasive disease caused by Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae, a review.Microbiology (Reading, England) · 2011Review
- Induction of efflux-mediated macrolide resistance in Streptococcus pneumoniae.Antimicrobial agents and chemotherapy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
Abstract
Streptococcus pneumoniae isolates (N = 31,001) were collected from patients with community-acquired respiratory tract infections during the PROTEKT US surveillance study (2000-2003). While the macrolide (erythromycin) resistance rate remained stable at approximately 29%, the prevalence of resistant isolates containing both erm(B) and mef(A) increased from 9.7% in year 1 to 16.4% in year 3, with substantial regional variability. Almost all (99.2%) dual erm(B) + mef(A) macrolide-resistant isolates exhibited multidrug resistance, whereas 98.6% and 99.0% were levofloxacin- and telithromycin-susceptible, respectively. These strains were most commonly isolated from the ear or middle-ear fluid of children. Of 152 representative erm(B)+mef(A) isolates, >90% were clonally related to the multidrug-resistant international Taiwan19F-14 clonal complex 271 (CC271). Of 366 erm(B)+mef(A) isolates from the PROTEKT global study (1999-2003), 83.3% were CC271, with the highest prevalence seen in South Africa, South Korea, and the United States. This study confirms the increasing global emergence and rapidly increasing US prevalence of this multidrug-resistant pneumococcal clone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.